Burleson & Company LLC lessened its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 2.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,932 shares of the company’s stock after selling 422 shares during the period. Eli Lilly And Co accounts for approximately 1.1% of Burleson & Company LLC’s investment portfolio, making the stock its 24th biggest holding. Burleson & Company LLC’s holdings in Eli Lilly And Co were worth $1,961,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. increased its position in Eli Lilly And Co by 3,062.5% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,783 shares of the company’s stock worth $237,000 after buying an additional 2,695 shares during the period. Smith Asset Management Group LP acquired a new position in Eli Lilly And Co during the second quarter worth approximately $65,407,000. Rice Hall James & Associates LLC acquired a new position in Eli Lilly And Co during the second quarter worth approximately $212,000. Victory Capital Management Inc. grew its stake in shares of Eli Lilly And Co by 5.6% in the 2nd quarter. Victory Capital Management Inc. now owns 20,797 shares of the company’s stock valued at $1,775,000 after purchasing an additional 1,104 shares during the last quarter. Finally, Global Financial Private Capital LLC grew its stake in shares of Eli Lilly And Co by 87.6% in the 2nd quarter. Global Financial Private Capital LLC now owns 6,714 shares of the company’s stock valued at $573,000 after purchasing an additional 3,135 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Shares of Eli Lilly And Co stock traded down $1.29 during trading on Thursday, reaching $115.23. The company’s stock had a trading volume of 435,859 shares, compared to its average volume of 4,456,462. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $119.84. The company has a market cap of $123.43 billion, a PE ratio of 26.92, a price-to-earnings-growth ratio of 1.82 and a beta of 0.31.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The firm had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the previous year, the business earned $1.05 earnings per share. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly And Co will post 5.58 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be paid a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 1.95%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.

Several brokerages have weighed in on LLY. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research note on Wednesday. ValuEngine upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, October 8th. Barclays lifted their target price on Eli Lilly And Co from $112.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, October 12th. Citigroup downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 target price on the stock. in a research note on Monday, November 26th. Finally, Cantor Fitzgerald set a $110.00 target price on Eli Lilly And Co and gave the company a “buy” rating in a research note on Monday, September 17th. Nine research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $111.53.

In related news, major shareholder Eli & Co Lilly sold 700,000 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total value of $9,800,000.00. Following the sale, the insider now directly owns 3,148,647 shares in the company, valued at $44,081,058. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $106.76, for a total value of $19,216,800.00. Following the completion of the sale, the insider now owns 119,832,753 shares in the company, valued at $12,793,344,710.28. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,127,300 shares of company stock worth $166,973,853. Company insiders own 0.11% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Eli Lilly And Co (LLY) Shares Sold by Burleson & Company LLC” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/eli-lilly-and-co-lly-shares-sold-by-burleson-company-llc/2665568.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Relative Strength Index

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.